|Mr. Robert W. Leasure Jr.||Pres, CEO & Director||797.4k||N/A||1960|
|Ms. Beth A. Taylor CPA||VP of Fin. & CFO||337.83k||N/A||1965|
|Dr. John E. Sagartz D.V.M., DiplomateACVP, DVM, Ph.D.||Chief Strategy Officer & Director||386.9k||N/A||1965|
|Dr. Peter T. Kissinger||Founder, Chairman Emeritus & Scientific Advisor||N/A||N/A||1945|
|Mr. Mark L. Bibi||Gen. Counsel & Sec.||N/A||N/A||1959|
|Ms. Kimberly Beaty||Sr. Director of Marketing||N/A||N/A||N/A|
|Mr. William D. Pitchford||Chief HR Officer||N/A||N/A||1955|
|Mr. Philip A. Downing||Sr. VP of Nonclinical Services||N/A||N/A||1970|
|Dr. J. Scott Daniels Ph.D.||Sr. VP of DMPK||N/A||N/A||N/A|
|Mr. John Gregory Beattie DSA||Chief Operating Officer of Discovery and Safety Assessment||N/A||N/A||1967|
Inotiv, Inc. provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment provides analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to identify and measure drug and metabolite concentrations in complex biological matrices; in vivo sampling services for the continuous monitoring of chemical changes in life; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; non-clinical toxicology and pathology services; and climate-controlled archiving services for its customers' data and samples. The Research Products segment designs, develops, manufactures, and markets in vivo sampling systems and accessories, including disposables, training, and systems qualification; physiology monitoring tools; liquid chromatography and electrochemistry instruments platforms; analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; and in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments. The company operates in the United States, rest of North America, the Pacific Rim, Europe, and internationally. It has an agreement with BioVaxys to conduct preclinical toxicity studies for its Covid-T Immunodiagnostic program. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana.
Inotiv, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.